University Hospitals Sussex NHS Foundation Trust is an NHS foundation trust which provides clinical services to people in Brighton and Hove, parts of East Sussex and West Sussex. It is abbreviated as UHSx to avoid confusion with University Hospital Southampton NHS Foundation Trust (UHS).
Purpose Although there are consistent guidelines of standardised glioblastoma patient care, there may be variation in treatments delivered due to differences in patient characteristics or adherence to guidelines across centres. This study explores the variation in treatments for glioblastoma patients across centres in a comprehensive multi-year brain tumour patient cohort in England. Methods We analysed data from the Gliocova project that contains over 50,000 adult brain tumour patients diagnosed between 2013 and 2018 in England. We selected a glioblastoma patient cohort and explored treatment rates, systemic predictors of treatment, variation in treatment across surgical centres and survival rates for different treatment groups. Results We analysed data from 11 359 patients with a histological diagnosis of GBM. Almost 80% of glioblastoma patients received at least some treatment after brain surgery, with 40% receiving the guideline recommended aggressive treatment (47% in the under-70s cohort). Age, sex, deprivation status, comorbidities, surgery type (resection versus biopsy) and ethnicity were identified as systemic predictors of receipt of post-operative treatment. There was also variation in receipt of post-operative treatment (64%-86%) and receipt of aggressive treatment (16%-65%) across centres. Patients receiving aggressive treatment had highest survival (15.6 months); in patients receiving any post operative treatment survival was 12.5 months and in patients receiving surgery only survival was 2.5 months. Conclusion 22% of glioblastoma patients undergoing surgery receive no further treatment and there is variation in post-surgical treatment both at centre and individual patient level. We suggest that centres should measure and report rates of no further treatment as part of standard clinical governance.
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p=0.057), gender (p=0.937), or proportion with performance status 0-1 (82.7% vs 68.3%, p=0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p<0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p<0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p=0.784). Overall survival (OS) from surgery was not different (p=0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43-0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24-0.95; median OS: 26.0 versus 14.0 months, p=0.031) but not biopsy (HR 1.10, 95% CI: 0.71-1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
Breast cancer risk is a central concern in shared decision-making when considering menopausal hormone treatment (MHT). Women spend approximately 40% of their lives in menopause, and climacteric symptoms can substantially impair quality of life. MHT is the most effective strategy to treat climacteric symptoms. MHT can consist of the administration of oestrogen only in women who have undergone hysterectomy or a combined treatment of oestrogen and progestogen in women with a uterus. The risk of breast cancer associated with MHT varies with both the individual's baseline risk of breast cancer and the type of treatment. Oestrogen only therapy in women who have undergone hysterectomy appears associated with a lower risk of breast cancer than combined oestrogen and progestogen MHT. Micronised progesterone and dydrogesterone seem associated with a lower risk of breast cancer than progestins, as shown in observational or case-control studies, but no randomised study has addressed this questions. Evaluating baseline risk of breast cancer before prescription of MHT should be considered a minimum standard alongside education on risk factors that can help decrease the risk of breast cancer with or without using MHT. This Review synthesises contemporary randomised and observational evidence, including pharmacologic distinctions, interaction with modifiable risk factors, and implications for better shared decision-making for women considering MHT.
BACKGROUND:Skin cancers primarily affect people of White ethnicity and with lighter skin tones, but people of other ethnicities may face diagnostic delays and experience higher mortality, reflecting existing inequities in healthcare. OBJECTIVES:To show incidence data from the National Disease Registration Service (NDRS) cancer registry in England for skin cancers, stratified by the seven broad ethnic groups. METHODS:We used data from the NDRS from 2013 to 2020 to analyse melanoma, acral lentiginous melanoma (ALM), basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), cutaneous T-cell lymphoma and Kaposi sarcoma (KS). Tumour records were linked to datasets including census population data, Office for National Statistics (ONS) mortality data, Index of Multiple Deprivation and Hospital Episode Statistics. Ethnicity data were grouped into seven standardized broad ONS categories: White, Asian, Chinese, Black, Mixed, Other and Unknown. European age-standardized rates (EASRs) were calculated using the 2013 European Standard Population and are reported per 100 000 person-years (PY). RESULTS:Ethnic diversity in England increased between the 2011 and 2021 censuses. Proportions of cases with 'Unknown' ethnicity with registry data ranged from 19.2% for BCC to 5.0% for ALM. The EASR (with 95% confidence interval) of melanoma was 33 times higher in the White group (27.3, 27.1-27.5) than in the Asian group (0.82, 0.67-0.99) and 16 times higher in the White than in the Black ethnic group (1.67, 1.37-2.01). Similarly, cSCC was 14 times more common in the White group (61.8, 61.5-62.0) than in the Asian group (4.55, 4.15-4.97) and 13 times more common in the White than in the Black ethnic group (4.73, 4.17-5.34). BCC was 26 times more common in the White group (154, 153-154) than in the Asian group (5.59, 5.16-6.04) and 27 times more common in the White than in the Black ethnic group (5.98, 5.35-6.65). However, the EASR for ALM was highest in the Black ethnic group. ALM was less likely to be referred along the Urgent Suspected Cancer pathway and was more likely to present at a later stage than melanoma overall. The EASR for KS was significantly higher in the Other and Black ethnic groups. CONCLUSIONS:A lack of high-quality published ethnicity data hampers our understanding of health disparities. These findings emphasize the need for better collection of ethnicity data and regular audits to better understand and address the needs of populations underserved by healthcare resources.
BACKGROUND:Respiratory syncytial virus (RSV) causes substantial winter pressure on adult services. In the UK, RSV vaccination currently targets adults aged ≥75 years and care home residents; it remains uncertain whether this age criterion alone meaningfully discriminates risk of poor outcome among adults hospitalised with RSV. METHODS:We pooled three UK hospital cohorts (one prospective, two retrospective) of adults admitted with acute respiratory infection (ARI) and PCR-confirmed RSV. The primary outcome was intensive care unit/high dependency unit (ICU/HDU) admission or all-cause mortality within 60 days. Prespecified predictors (age, sex and comorbidities) entered a least absolute shrinkage and selection operator (LASSO) penalised logistic regression; selected variables were refitted using standard logistic regression. Discrimination, calibration and decision-analytic performance were assessed using 1000-bootstrap internal validation and decision-curve analysis. RESULTS:Among 334 adults, 37 (11.1%) experienced the primary outcome. An age-only rule mirroring current UK vaccine age-eligibility (≥75 years) demonstrated only modest discrimination (optimism-adjusted area under the receiver operating characteristic curve (AUC) 0.58, 95% CI 0.48 to 0.65) and a compressed distribution of predicted risks. A four-predictor model-including age, COPD, active/previous cancer and dementia-achieved higher discrimination AUC (0.77 (0.69 to 0.85)), a wider spread of predicted risks and the greatest net benefit across clinically plausible escalation thresholds (5-20%). CONCLUSIONS:In adults hospitalised with RSV-associated ARI, simple age-based heuristics-including the UK ≥75-year threshold-showed only modest ability to discriminate risk of ICU/HDU admission/60-day mortality once hospitalised. Comorbidity-inclusive approaches may provide more informative hospital-level risk stratification and warrant evaluation in future RSV vaccine-effectiveness and outcome studies. Any application requires external validation, more systematic RSV testing and comparison with physiology-based scores in larger, vaccinated cohorts.